South Korea · Delayed Price · Currency is KRW Biotoxtech Statistics
Total Valuation
Biotoxtech has a market cap or net worth of KRW 42.45 billion. The enterprise value is 73.47 billion.
| Market Cap | 42.45B |
| Enterprise Value | 73.47B |
Important Dates
The next estimated earnings date is Friday, March 20, 2026.
| Earnings Date | Mar 20, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Biotoxtech has 15.72 million shares outstanding. The number of shares has increased by 20.43% in one year.
| Current Share Class | 15.72M |
| Shares Outstanding | 15.72M |
| Shares Change (YoY) | +20.43% |
| Shares Change (QoQ) | +14.64% |
| Owned by Insiders (%) | 15.02% |
| Owned by Institutions (%) | n/a |
| Float | 10.38M |
Valuation Ratios
The trailing PE ratio is 123.17.
| PE Ratio | 123.17 |
| Forward PE | n/a |
| PS Ratio | 0.96 |
| PB Ratio | 1.25 |
| P/TBV Ratio | 1.04 |
| P/FCF Ratio | 16.12 |
| P/OCF Ratio | 8.96 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 83.54 |
| EV / Sales | 1.66 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 27.90 |
Financial Position
The company has a current ratio of 0.63, with a Debt / Equity ratio of 1.84.
| Current Ratio | 0.63 |
| Quick Ratio | 0.39 |
| Debt / Equity | 1.84 |
| Debt / EBITDA | n/a |
| Debt / FCF | 23.85 |
| Interest Coverage | -1.15 |
Financial Efficiency
Return on equity (ROE) is -9.79% and return on invested capital (ROIC) is 15.97%.
| Return on Equity (ROE) | -9.79% |
| Return on Assets (ROA) | -2.78% |
| Return on Invested Capital (ROIC) | 15.97% |
| Return on Capital Employed (ROCE) | -12.48% |
| Weighted Average Cost of Capital (WACC) | -6.66% |
| Revenue Per Employee | 235.06M |
| Profits Per Employee | 4.68M |
| Employee Count | 188 |
| Asset Turnover | 0.32 |
| Inventory Turnover | 3.00 |
Taxes
In the past 12 months, Biotoxtech has paid 5.55 billion in taxes.
| Income Tax | 5.55B |
| Effective Tax Rate | 278.86% |
Stock Price Statistics
The stock price has decreased by -20.15% in the last 52 weeks. The beta is 0.38, so Biotoxtech's price volatility has been lower than the market average.
| Beta (5Y) | 0.38 |
| 52-Week Price Change | -20.15% |
| 50-Day Moving Average | 2,708.70 |
| 200-Day Moving Average | 2,899.43 |
| Relative Strength Index (RSI) | 49.56 |
| Average Volume (20 Days) | 28,393 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Biotoxtech had revenue of KRW 44.19 billion and earned 879.45 million in profits. Earnings per share was 21.92.
| Revenue | 44.19B |
| Gross Profit | 4.37B |
| Operating Income | -6.22B |
| Pretax Income | 1.99B |
| Net Income | 879.45M |
| EBITDA | -1.92B |
| EBIT | -6.22B |
| Earnings Per Share (EPS) | 21.92 |
Balance Sheet
The company has 23.71 billion in cash and 62.82 billion in debt, with a net cash position of -39.11 billion or -2,487.57 per share.
| Cash & Cash Equivalents | 23.71B |
| Total Debt | 62.82B |
| Net Cash | -39.11B |
| Net Cash Per Share | -2,487.57 |
| Equity (Book Value) | 34.06B |
| Book Value Per Share | 2,735.32 |
| Working Capital | -30.31B |
Cash Flow
In the last 12 months, operating cash flow was 4.74 billion and capital expenditures -2.10 billion, giving a free cash flow of 2.63 billion.
| Operating Cash Flow | 4.74B |
| Capital Expenditures | -2.10B |
| Free Cash Flow | 2.63B |
| FCF Per Share | 167.51 |
Margins
Gross margin is 9.88%, with operating and profit margins of -14.07% and 1.99%.
| Gross Margin | 9.88% |
| Operating Margin | -14.07% |
| Pretax Margin | 4.50% |
| Profit Margin | 1.99% |
| EBITDA Margin | -4.36% |
| EBIT Margin | -14.07% |
| FCF Margin | 5.96% |
Dividends & Yields
Biotoxtech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -20.43% |
| Shareholder Yield | -20.43% |
| Earnings Yield | 2.07% |
| FCF Yield | 6.20% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Biotoxtech has an Altman Z-Score of 0.24 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.24 |
| Piotroski F-Score | 6 |